Next 10 |
2024-07-02 12:04:07 ET More on Alvotech Alvotech (ALVO) Q1 2024 Earnings Call Transcript Alvotech 2024 Q1 - Results - Earnings Call Presentation Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech issues new shares to holders of converti...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia ® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endp...
2024-07-01 17:42:57 ET More on Alvotech Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech and Stada add to strategic alliance through denosumab partnership Alvotech enters $965M refinancing agreement Read the full article on Seeking ...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvote...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter a...
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issue...
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea ® in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access ...
2024-06-11 04:33:48 ET More on Alvotech Alvotech (ALVO) Q1 2024 Earnings Call Transcript Alvotech 2024 Q1 - Results - Earnings Call Presentation Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech enters $965M refinancing agreement ...
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia ® /Xgeva ® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle East This partnership for the osteoporosis an...
2024-06-07 10:57:58 ET Summary Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter o...
News, Short Squeeze, Breakout and More Instantly...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia ® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endp...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvote...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter a...